Wong GLH, Wong VWS, Yuen BWY, et al. - In 2000–2017, researchers determined the prevalence of key comorbidities and concomitant medications in a territory-wide chronic hepatitis B (CHB) cohort in Hong Kong, China. Through the Clinical Data Analysis and Reporting System of the Hospital Authority, Hong Kong, patients with CHB who have been under the care at primary, secondary, and tertiary medical centers in the public sector were identified. The study sample consisted of 135,395 patients with CHB. Findings revealed a trend of increasing prevalence of several common comorbidities over the four periods evaluated (000-2004, 2005-2009, 2010-2013, and 2014-2017): hypertension 25.5%, 23.8%, 27.2%, and 28.6%; diabetes mellitus 10.6%, 12.5%, 16.1%, and 20.1%; cardiovascular disease 12.5%, 16.9%, 20.9%, and 22.2%; and malignancy 7.0%, 13.2%, 17.3%, and 23.6%. The researchers recommended that, when choosing antiviral treatment, these comorbidities should be considered.